Pradaxa Internal Bleeding Lawsuit Status Conference to Occur, Pradaxa Plaintiffs Lawyers See Medical Reports as Positive for Their Clients' Claims

Mark Niemeyer, Co-Liaison Counsel in the Pradaxa Products Liability Litigation Continues to Fight for the Families of Those Suffering Internal Bleeding after Using the Anticoagulant Pradaxa

  • Share on TwitterShare on FacebookShare on Google+Share on LinkedInEmail a friend
Mark Niemeyer

Mark Niemeyer

On behalf of the plaintiffs, we continue to keep pressure on the Defendants to produce those documents that discuss the aggressive marketing of Pradaxa despite safety concerns as we work toward the first trial next summer.

St. Louis, MO (PRWEB) July 08, 2013

A Status Conference will occur on July 9, 2013 in the Pradaxa Products Liability Litigation (MDL No. 2385, United States District Court, Southern District of Illinois) to discuss topics including the Defendant's document production schedule and the bellwether trial process. Bellwether trials serve as representative trials in Multi-District Litigation, such as the Pradaxa internal bleeding lawsuit, and allow the parties to organize their pretrial discovery and evaluate the strengths of their case. The first bellwether trial for Pradaxa is set for August of 2014.

Pradaxa is an anticoagulant manufactured by Boehringer Ingelheim Pharmaceuticals, Inc. that was approved by the FDA in 2010 to prevent stroke in people with atrial fibrillation, often referred to as AFib, which is the most commonly diagnosed arrhythmia, affecting more than 2.6 million Americans. Pradaxa was the first anticoagulant approved since warfarin was approved in the early 1950s. Some users of Pradaxa experienced severe internal bleeding, some of which resulted in death, leading to Pradaxa lawsuits. Pradaxa lawyers allege that the maker of the drug did not adequately warn users of the risk and danger from internal bleeding. A January 2013 report by the Institute for Safe Medication Practices (ismp.org/quarterwatch/pdfs/2012Q2.pdf) compared serious adverse drug events reported to the FDA under the FDA Adverse Event Reporting System, also known as MedWatch, for Pradaxa, Xarelto and warfarin during the second quarter of 2012. It found that the three anticoagulants accounted for 1,734 reports to the FDA, including 233 deaths, during the three-month period. The Institute's analysis of the three drugs found that Pradaxa use resulted in death nearly two and a half times as frequently as Xarelto and almost five times greater than warfarin.

Mark Niemeyer and the pharmaceutical litigation team at Onder, Shelton, O’Leary & Peterson, LLC are offering a free Pradaxa lawsuit case review with no further obligation to the families of persons who experienced severe internal bleeding after using Pradaxa. Pradaxa claims are being handled on a contingency basis with no cost to the client unless they successfully win compensation for them. Although the firm is centrally located in St. Louis, Missouri, it represents clients throughout the United States. St. Louis is the closest metropolitan area to the court handling the Pradaxa Products Liability Litigation.

Niemeyer also invites other attorneys to consult with a Pradaxa lawyer at the firm, which are available either to handle those cases or work as co-counsel.

About The Onder Law Firm
Onder, Shelton, O’Leary & Peterson, LLC is a St. Louis based personal injury law firm handling serious injury and death claims across the country. Its mission is the pursuit of justice, no matter how complex the case or strenuous the effort. Onder, Shelton, O’Leary & Peterson has represented clients throughout the United States, and other firms throughout the nation often seek its experience and expertise on complex litigation. It is a recognized leader in products liability cases such as window blind cord strangulation and pharmaceutical litigation. The Onder Law Firm offers information pertaining to Pradaxa internal bleeding dangers at http://www.pradaxalawsuitcenter.com.


Contact